New MRI dye could spot hidden cancer in brain lining

NCT ID NCT07415018

Recruiting now Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a new contrast agent called gadopiclenol (VUEWAY) can improve MRI scans to detect leptomeningeal disease (LMD), a condition where cancer spreads to the lining of the brain and spinal cord. Researchers will compare it to the standard contrast agent gadobutrol (Gadavist) in 40 adults with solid tumors who may have LMD. The goal is to see if the new dye makes early signs of LMD more visible, potentially leading to faster diagnosis and treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gadopiclenol (VUEWAY) and gadobutrol (Gadavist)
What this could lead to: If successful, this could lead to a more accurate MRI method for detecting leptomeningeal disease early, helping doctors diagnose and treat this serious condition sooner.
What could go wrong: This is a small, early-phase study with only 40 participants, so results may not apply to everyone. The new contrast agent might not prove significantly better than current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Meningeal Neoplasms neoplastic meningitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEPTOMENINGEAL DISEASE

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.